KR20250002557A - 암의 치료를 위한 ras 억제제 및 파르네실트랜스퍼라제 억제제의 조합 - Google Patents

암의 치료를 위한 ras 억제제 및 파르네실트랜스퍼라제 억제제의 조합 Download PDF

Info

Publication number
KR20250002557A
KR20250002557A KR1020247038308A KR20247038308A KR20250002557A KR 20250002557 A KR20250002557 A KR 20250002557A KR 1020247038308 A KR1020247038308 A KR 1020247038308A KR 20247038308 A KR20247038308 A KR 20247038308A KR 20250002557 A KR20250002557 A KR 20250002557A
Authority
KR
South Korea
Prior art keywords
cancer
ras
inhibitor
subject
farnesyltransferase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247038308A
Other languages
English (en)
Korean (ko)
Inventor
올리비에 깔베이학
질 파브르
셀리아 드라애
Original Assignee
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔)
상뜨로 나쇼날 드 라 러쉐르쉐 샹띠피크
엥스띠뛰 끌로디우스 헤고
위니베르씨떼 뚤루즈 3 - 뽈 싸바띠에
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔), 상뜨로 나쇼날 드 라 러쉐르쉐 샹띠피크, 엥스띠뛰 끌로디우스 헤고, 위니베르씨떼 뚤루즈 3 - 뽈 싸바띠에 filed Critical 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔)
Publication of KR20250002557A publication Critical patent/KR20250002557A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247038308A 2022-04-28 2023-04-27 암의 치료를 위한 ras 억제제 및 파르네실트랜스퍼라제 억제제의 조합 Pending KR20250002557A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP22305636 2022-04-28
EP22305636.7 2022-04-28
EP22306602.8 2022-10-21
EP22306602 2022-10-21
PCT/EP2023/061079 WO2023209073A1 (en) 2022-04-28 2023-04-27 Combination of ras inhibitors and farnesyltransferase inhibitors for the treatment of cancers

Publications (1)

Publication Number Publication Date
KR20250002557A true KR20250002557A (ko) 2025-01-07

Family

ID=86378289

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247038308A Pending KR20250002557A (ko) 2022-04-28 2023-04-27 암의 치료를 위한 ras 억제제 및 파르네실트랜스퍼라제 억제제의 조합

Country Status (5)

Country Link
US (1) US20250262211A1 (https=)
EP (1) EP4514356A1 (https=)
JP (1) JP2025513929A (https=)
KR (1) KR20250002557A (https=)
WO (1) WO2023209073A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4719410A1 (en) * 2023-05-31 2026-04-08 Kura Oncology, Inc. Farnesyltransferase inhibitors for treatment of kras-dependent cancers

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140335077A1 (en) * 2013-05-07 2014-11-13 Leonard Girnita Compositions and Methods for the Treatment of Cancer Using IGF-IR Antagonists and MAPK/ERK Inhibitors
US11331312B2 (en) * 2014-04-25 2022-05-17 Memorial Sloan-Kettering Cancer Center Treatment of H-Ras-driven tumors
US20230285498A1 (en) * 2020-08-07 2023-09-14 City Of Hope Treatments for cancers having kras mutations

Also Published As

Publication number Publication date
WO2023209073A1 (en) 2023-11-02
US20250262211A1 (en) 2025-08-21
EP4514356A1 (en) 2025-03-05
JP2025513929A (ja) 2025-04-30

Similar Documents

Publication Publication Date Title
US20220401436A1 (en) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
JPWO2020130125A1 (ja) 抗体−薬物コンジュゲートとキナーゼ阻害剤の組み合わせ
CN110325191A (zh) 以较少的副作用治疗egfr-驱动的癌症
JP2021525244A (ja) 腫瘍性疾患を治療するための薬剤の調製におけるｅｇｆｒ阻害剤と組み合わせたｃｄｋ４／６阻害剤の使用
US20250262211A1 (en) Combination of ras inhibitors and farnesyltransferase inhibitors for the treatment of cancers
ES3030540T3 (en) Treatment of breast cancer using combination therapies comprising gdc-9545 and gdc-0077
CN118973584A (zh) Kras g12c抑制剂和tead抑制剂的治疗组合
AU2015266552A1 (en) Pharmaceutical composition comprising pyrazine carboxamide compound as active ingredient
US20250186438A1 (en) Treatment of clear cell renal cell carcinoma
CN118829432A (zh) 用于治疗癌症的ras抑制剂和法尼基转移酶抑制剂的组合
EP4536648A1 (en) Novel ras inhibitors
US9566334B2 (en) Combinations of a PI3K/AKT inhibitor compound with an HER3/EGFR inhibitor compound and use thereof in the treatment of a hyperproliferative disorder
EP4213854A1 (en) Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds for treating adenoid cystic carcinoma
US20250339387A1 (en) Mitoxanthrone derivatives as ras inhibitors
WO2023242107A1 (en) Novel ras inhibitors
Hudson Targeting met receptor tyrosine kinase for cancer therapy: Design, characterization, and preclinical validation of a novel anti-met antibody-drug conjugate
EP4536665A1 (en) Novel ras inhibitors
WO2023242103A1 (en) Novel ras inhibitors
EP4536203A1 (en) Diaminoacridine derivatives as inhibitors of ras
EP4536360A1 (en) Novel ras inhibitors
JP2024531136A (ja) Ｖａｖ３がんの治療のためのｉｏｄｖａ１化合物との組み合わせ療法
Kissel et al. 207 A novel selective MET inhibitor combined with erlotinib overcomes erlotinib facilitated resistance in patient derived NSCLC xenografts in vivo

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000